Inventor · disambiguated record
Toshiaki Wakabayashi
Also filed as: WAKABAYASHI TOSHIAKI
7 granted patents·5 pending applications·106 citations·filing 1999–2010
83Inventor score
Top patents by PatentIndex Score
12 records- 0193US6787534B2Sulfonamide-containing heterocyclic compoundsEISAI CO LTD·Filed 2000·Granted Sep 7, 2004·82 cites·9 claims
- 0280US6469043B1Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2000·Granted Oct 22, 2002·13 cites·22 claims
- 0370US6673787B2Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2002·Granted Jan 6, 2004·4 cites·19 claims
- 0468US6638964B2Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2002·Granted Oct 28, 2003·3 cites·9 claims
- 0557US2009269352A1Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitorWAKABAYASHI TOSHIAKI·Filed 2009·Application pending·0 cites
- 0656US7122318B2Method for testing effect of angiogenesis inhibitor via integrin expression inhibitionEISAI CO LTD·Filed 2002·Granted Oct 17, 2006·3 cites·24 claims
- 0755US7834049B2Integrin expression inhibitorEISAI R&D MAN CO LTD·Filed 2005·Granted Nov 16, 2010·0 cites·4 claims
- 0847US2005119303A1Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with an angiogenesis inhibitorEISAI CO LTD·Filed 2003·Application pending·0 cites
- 0947US2010267754A1Integrin expression inhibitorWAKABAYASHI TOSHIAKI·Filed 2010·Application pending·0 cites
- 1046US2004018192A1Integrin expression inhibitorsFiled 2001·Application pending·0 cites
- 1142US2009047278A1Novel Combinational Use of Sulfonamide CompoundEISAI R&D MAN CO LTD·Filed 2006·Application pending·0 cites
- 1224US6645996B1Physiologically active substancesMERCIAN CORP AND EISAI CO LTD·Filed 1999·Granted Nov 11, 2003·1 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Toshiaki Wakabayashi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →